WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Biotech-365
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
MedTech
Genscript | August 18, 2022
GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of a new research use only and pre-clinical messenger RNA synthesis service for biopharma research and development teams. By applying decades of experience in molecular biology, GenScript now offers a single-vendor gene-to-mRNA service that delivers custom mRNA within six to eight weeks. mRNA provides new therapeutic opportunities for a range of diseases, and s...
Cell and Gene Therapy
Biotimize | September 06, 2022
Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, today announced the opening of a $30 million Series A fundraising round. The investment will enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America. Brazilian universities, startups, and medium-large companies face enormous challenges in developing biological Active Pharmaceutical...
Industrial Impact
Chimeron Bio | January 25, 2022
Chimeron Bio, a biotechnology company pioneering a novel class of self-amplifying RNA-vaccines and therapeutics announced its plan to expand operations in the Philadelphia area and move to The Curtis, a landmark site in Center City Philadelphia under BioLabs, the leading developer and operator of life science co-working spaces in the U.S. and internationally. The move stems from Chimeron’s need for an expanded footprint to accommodate its growing R&D team and operations....
Intravacc | August 18, 2020
Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine, of a clinical phase I study with its candidate Respiratory Syncytial Virus (RSV) vaccine. The vaccine showed excellent induction of immunogenicity after nasal administration to healthy adult volunteers (18-50 years). In addition, the Live Attenuated Vaccine (LAV), constructed with reverse genetics, appears to be safe and well-tolera...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE